Physician profile
Peter Stan
NPI 1710569819
$857.53
in general payments reported to CMS, 2019-2025
13 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $48.21 · 2023: $90.97 · 2024: $167 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $150.00 | 2025 | |
| Rxsight INC | $142.62 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Harrow Eye, LLC | $116.27 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $111.12 | 2023-2024 | |
| Omeros Corporation | $73.82 | 2021 | |
| Bausch & Lomb Americas INC. | $45.38 | 2024-2025 | Miebo |
| Abbvie INC. | $42.16 | 2023 | Durysta |
| Sun Pharmaceutical Industries INC. | $41.81 | 2024-2025 | |
| Kala Pharmaceuticals, INC. | $38.10 | 2021-2022 | |
| Horizon Therapeutics Plc | $28.24 | 2022 | |
| Alcon Vision LLC | $27.35 | 2021-2025 | Precision7 |
| New World Medical,INC. | $21.37 | 2024 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Dompe US, INC. | $19.29 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Stan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.